Verrica Pharmaceuticals Inc.
VRCA
$6.73
-$0.82-10.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 905.39% | 145.35% | -10.12% | -82.70% | -161.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 905.39% | 145.35% | -10.12% | -82.70% | -161.06% |
| Cost of Revenue | 16.69% | -39.39% | -55.29% | -67.95% | -58.11% |
| Gross Profit | 338.69% | 687.39% | 131.77% | 59.82% | -19.62% |
| SG&A Expenses | -41.53% | -46.42% | -45.85% | -41.87% | -19.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.80% | -45.09% | -48.41% | -48.33% | -29.48% |
| Operating Income | 107.86% | 109.93% | 56.29% | 45.01% | 13.43% |
| Income Before Tax | 98.80% | 101.19% | 52.08% | 34.18% | 7.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 98.80% | 101.19% | 52.08% | 34.18% | 7.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.80% | 101.19% | 52.08% | 34.18% | 7.83% |
| EBIT | 107.86% | 109.93% | 56.29% | 45.01% | 13.43% |
| EBITDA | 108.49% | 110.94% | 56.40% | 45.54% | 14.00% |
| EPS Basic | 99.41% | 100.58% | 76.51% | 54.72% | 9.27% |
| Normalized Basic EPS | 99.41% | 100.58% | 76.51% | 49.78% | 9.27% |
| EPS Diluted | 99.41% | 100.54% | 76.51% | 54.72% | 9.27% |
| Normalized Diluted EPS | 99.41% | 100.58% | 76.51% | 49.78% | 9.27% |
| Average Basic Shares Outstanding | 102.76% | 104.04% | 104.02% | 45.38% | 1.59% |
| Average Diluted Shares Outstanding | 102.76% | 104.09% | 104.02% | 45.38% | 1.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |